𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy

✍ Scribed by Alfonso Quintás-Cardama; Hagop Kantarjian; Farhad Ravandi; Susan O'Brien; Deborah Thomas; Gabriela Vidal-Senmache; William Wierda; Steven Kornblau; Jorge Cortes

Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
143 KB
Volume
115
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib mesylate therapy reduces bone m
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
✍ Carlos E. Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 189 KB 👁 1 views

## Abstract ## BACKGROUND Reticulin‐stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML). Resolution of fibrosis with therapy may improve patient outcome. ## METHODS The effect of imatinib therapy on bone marrow fibrosis was evaluat

Therapeutic choices in younger patients
Therapeutic choices in younger patients with chronic myelogenous leukemia
✍ Hagop M. Kantarjian; Francis J. Giles; Susan O'Brien; Sergio Giralt; Moshe Talpa 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB 👁 2 views

## Background: Allogeneic stem cell transplantation (sct) and interferon (ifn)-alpha therapy have significantly improved the prognosis of patients with philadelphia (ph) chromosome positive chronic myelogenous leukemia (cml). both therapies may be suitable for younger patients. the authors reviewed

Prognostic impact of deletions of deriva
Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib
✍ Alfonso Quintás-Cardama; Hagop Kantarjian; Jianqin Shan; Elias Jabbour; Lynne V. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 230 KB

## Abstract ## BACKGROUND: Deletions of derivative chromosome 9 are a poor prognostic factor in patients with chronic myeloid leukemia (CML) treated with hydroxyurea, interferon, or stem cell transplantation. Imatinib may overcome the adverse prognostic impact of deletions of derivative chromosome

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 82 KB 👁 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression ≥ Grade 3, requiring interruption of thera

Dynamics and management of cytopenias as
Dynamics and management of cytopenias associated with dasatinib therapy in patients with chronic myeloid leukemia in chronic phase after imatinib failure
✍ Alfonso Quintás-Cardama; Fabio Pires De Souza Santos; Hagop Kantarjian; Susan O' 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 160 KB 👁 2 views

## Abstract ## BACKGROUND: The incidence, dynamics, and management of cytopenias were investigated in patients with chronic myeloid leukemia in chronic phase (CP CML) who received dasatinib therapy after imatinib failure. ## METHODS: Data were analyzed from 130 patients with CP CML who were trea